trending Market Intelligence /marketintelligence/en/news-insights/trending/lfsMlJkoh7dahxHbrJFCYg2 content esgSubNav
In This List

Antisense completes A$1.6M placement for Duchenne muscular dystrophy drug

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Antisense completes A$1.6M placement for Duchenne muscular dystrophy drug

Antisense Therapeutics Ltd. completed a private placement of 48,484,849 common shares, raising about A$1.6 million in gross proceeds.

The Australian pharmaceutical company, based in Toorak, Victoria, issued the shares for 3.3 Australian cents apiece.

Antisense Therapeutics previously said it plans to use proceeds to fund development of its product candidate ATL1102 to treat Duchenne muscular dystrophy, or DMD, a genetic disorder characterized by progressive muscle degeneration and weakness that could lead to death.

Antisense Therapeutics develops therapies to treat diseases including DMD, multiple sclerosis and acromegaly.